The Adherence Problem in Cancer Care
One of oncology's most persistent and underappreciated challenges is treatment adherence. Patients prescribed oral cancer medications — hormone therapies, targeted drugs, or immunomodulatory agents — often discontinue their treatment before completing the prescribed course. Studies have consistently found that 20 to 50 percent of breast cancer patients on oral adjuvant therapy stop taking their medication within the first year, usually without telling their oncologist. The consequences can be serious: these medications are prescribed because they demonstrably improve survival rates, and stopping them prematurely eliminates that benefit.
A new study has found that regular telehealth check-ins — virtual appointments with a nurse or oncologist conducted via video or phone — significantly improve treatment adherence among breast cancer patients. The findings add to the growing evidence base for telehealth as a meaningful clinical tool, not just a convenience feature.
Study Design and Results
The study followed approximately 800 breast cancer patients at multiple cancer centers who had been prescribed oral adjuvant therapies, including aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized into two groups: one received standard care with in-person oncology appointments at typical intervals of three to six months, while the other received standard care supplemented by monthly telehealth check-ins with a nurse navigator.
After one year, the telehealth group showed significantly higher medication adherence — 78 percent remained on their prescribed therapy versus 61 percent in the standard care group, a 17 percentage point difference that was statistically significant. The telehealth group also reported lower levels of treatment-related anxiety and better management of side effects, which the researchers identified as the primary mechanism driving the adherence improvement.
Side effects are the leading reason breast cancer patients stop taking oral therapies. Aromatase inhibitors, for example, commonly cause joint pain, hot flashes, and fatigue that patients often tolerate in silence rather than reporting at a quarterly appointment. Monthly telehealth calls gave nurse navigators the opportunity to identify side effect complaints early, offer management strategies, and connect patients with supportive care resources before side effects became severe enough to prompt medication discontinuation.
Why This Matters
The clinical significance of a 17 percentage point improvement in adherence is substantial. Adjuvant hormone therapy for breast cancer is typically prescribed for five to ten years, and research has shown that completing the full course reduces the risk of cancer recurrence by 30 to 50 percent compared to stopping early. If telehealth check-ins can keep an additional 17 percent of patients on therapy, the downstream impact on survival outcomes becomes meaningful at population scale.
The study also has implications for healthcare equity. Breast cancer patients who face the greatest barriers to frequent in-person care — those in rural areas, those with transportation challenges, those with demanding work or caregiving schedules — are also often the patients most likely to lose touch with their oncology team and discontinue treatment. Telehealth check-ins are accessible from any location with a phone or internet connection, making them a powerful tool for reaching patients who would otherwise fall through the care gaps between quarterly appointments.
Practical and Policy Implications
The research arrives at a moment when telehealth policy in the US remains in flux. Pandemic-era expansions of Medicare and Medicaid telehealth coverage have been extended multiple times but never made permanent. Oncology professional organizations have advocated for permanent telehealth coverage as the evidence base for its clinical effectiveness has grown, and studies like this one provide the outcome data that insurance coverage decisions ultimately require.
For cancer centers and oncology practices, the study points toward a care model in which high-frequency, low-overhead telehealth contact supplements rather than replaces periodic in-person visits. The monthly nurse navigator call is not a replacement for the comprehensive quarterly oncology appointment — it is a safety net that catches problems before they become catastrophic, keeping patients engaged with their care team through what is often a grueling multi-year treatment regimen.
This article is based on reporting by STAT News. Read the original article.
